Compare · BLLN vs ILMN
BLLN vs ILMN
Side-by-side comparison of BillionToOne Inc. (BLLN) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLLN and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $33.97B, about 7.2x BLLN ($4.72B).
- Over the past year, BLLN is down 8.9% and ILMN is up 127.9% - ILMN leads by 136.8 points.
- ILMN has been more active in the news (11 items in the past 4 weeks vs 9 for BLLN).
- ILMN has more recent analyst coverage (25 ratings vs 8 for BLLN).
- Company
- BillionToOne Inc.
- Illumina Inc.
- Price
- $99.97+3.07%
- $225.01+0.76%
- Market cap
- $4.72B
- $33.97B
- 1M return
- -21.79%
- +18.79%
- 1Y return
- -8.89%
- +127.94%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- 2000
- News (4w)
- 9
- 11
- Recent ratings
- 8
- 25
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest BLLN
- Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
- SVP of Laboratory Operations Ten Bosch John Roderick sold $131,583 worth of shares (1,417 units at $92.86) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 27,884 units (SEC Form 4)
- Chief Technology Officer Tsao David exercised 10,000 shares at a strike of $2.80 and sold $928,600 worth of shares (10,000 units at $92.86) as part of a pre-agreed trading plan (SEC Form 4)
- Chairman and CEO Atay Oguzhan exercised 15,539 shares at a strike of $2.80 and sold $2,331,352 worth of shares (15,539 units at $150.03) as part of a pre-agreed trading plan (SEC Form 4)
- Chairman and CEO Atay Oguzhan exercised 32,500 shares at a strike of $2.80 and sold $6,167,960 worth of shares (45,000 units at $137.07) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by BillionToOne Inc.
- BillionToOne Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
- Chief Product Officer Sakakibara Shan Riku sold $560,840 worth of shares (4,000 units at $140.21) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 200,000 units (SEC Form 4)
- Officer Johnson Nancy Joann sold $1,821,628 worth of shares (14,199 units at $128.29) as part of a pre-agreed trading plan, decreasing direct ownership by 67% to 6,900 units (SEC Form 4)
Latest ILMN
- Director Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)
- SVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)
- SEC Form 8-K filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 8-K filed by Illumina Inc.
- SEC Form 3 filed by new insider Coletti Julie Ann
- SEC Form FWP filed by Illumina Inc.
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)